Alkem Laboratories Ltd
NSE:ALKEM

Watchlist Manager
Alkem Laboratories Ltd Logo
Alkem Laboratories Ltd
NSE:ALKEM
Watchlist
Price: 5 675.5 INR 0.29% Market Closed
Market Cap: 678.6B INR

Alkem Laboratories Ltd
Investor Relations

Alkem Laboratories Ltd., founded in 1973, has emerged as a significant player in India's pharmaceutical landscape, deftly combining innovation with a robust distribution network. Anchored in Mumbai, Alkem began as a modest venture but quickly evolved into a powerhouse, renowned for manufacturing a broad spectrum of branded generics, over-the-counter products, and active pharmaceutical ingredients (APIs). The company's success lies in its ability to cater to both domestic and international markets, primarily thriving on the ever-increasing demand for affordable healthcare solutions. Its formidable market presence in India is supported by a strong sales force and an extensive distribution network, ensuring its therapies reach even the most remote corners of the country.

Internationally, Alkem has carved a niche for itself, with the United States being one of its major export markets. It strategically entered this competitive arena, building a portfolio of ANDAs (Abbreviated New Drug Applications) that allowed it to provide lower-cost alternatives to big pharma's patented drugs. This not only fueled its revenue growth but also fortified its standing as a go-to source for quality generics. Alkem's research and development efforts underpin its commitment to healthcare innovation, as it constantly seeks to expand its therapeutic repertoire. By consistently focusing on quality, affordability, and resourceful adaptation to global healthcare needs, Alkem Laboratories Ltd. has managed to script a growth story that is both impressive and sustainable.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q2 2026
Call Date
Nov 13, 2025
AI Summary
Q2 2026

Record Revenue: Alkem reported all-time high revenue from operations of INR 40,010 million in Q2 FY '26, up 17.2% year-on-year.

Strong Growth Across Markets: India business grew 12.4% YoY, U.S. sales jumped 28%, and non-U.S. international sales surged 32.4%.

EBITDA & Margins: EBITDA grew 22.3% YoY to INR 9,208 million, with an EBITDA margin of 23%. Management raised full-year guidance to 19.5–20% EBITDA margin, up from earlier 19.5%.

Profitability: Net profit after minority interest was INR 7,651 million, up 11.1% YoY.

Guidance Maintained: Management expects double-digit growth for the rest of FY '26 and to continue outperforming the market by 100–150 bps, with similar trends likely in FY '27.

CDMO & Medtech Ramp-Up: U.S. CDMO plant now operational; expects INR 20 crore per quarter revenue and INR 50 crore per quarter OpEx in H2. Medtech and Adroit businesses are small but growing, with Medtech running at a loss and Adroit at breakeven.

GST Impact: GST revision caused a transient INR 10–12 crore impact and will reduce Sikkim facility benefits by INR 50–60 crore in H2.

Future Margin Expansion: Management targets at least 1% annual margin improvement from FY '27 onwards, including planned investments.

Key Financials
Revenue
INR 40,010 million
India Sales
INR 27,660 million
U.S. Sales
INR 7,649 million
Non-U.S. International Sales
INR 4,241 million
EBITDA
INR 9,208 million
EBITDA Margin
23%
Net Profit after Minority Interest
INR 7,651 million
R&D Expense
INR 1,302 million
Gross Margin
65%
Medtech Revenue
INR 2.5 crore
Medtech EBITDA Loss
INR 5.5 crore
Adroit Revenue
INR 15 crore
Enzene U.S. CDMO Revenue
INR 15–20 crore per quarter
Enzene U.S. CDMO OpEx
INR 50 crore per quarter
Pune CDMO Revenue
INR 25–30 crore per quarter
Sikkim GST Benefit Impact
INR 50–60 crore in H2
Other Expenses
INR 900–905 crore per quarter (Q3 & Q4 projection)
Effective Tax Rate
35–38% expected for FY '27
Earnings Call Recording
Other Earnings Calls

Management

Mr. Basudeo Narian Singh
Executive Chairman
No Bio Available
Mr. Sarvesh Singh
VP of Sales & Marketing and Executive Director
No Bio Available
Mr. Sandeep Derjit Singh
MD & Executive Director
No Bio Available
Ms. Madhurima Singh
Executive Director
No Bio Available
Dr. Vikas Gupta
Chief Executive Officer
No Bio Available
Dr. Akhilesh D. Sharma
President & Chief Medical Officer
No Bio Available
Mr. Kaustav Banerjee
President & Head Medtech Business
No Bio Available
Mr. Rajorshi Ganguli
President & Global HR Head
No Bio Available

Contacts

Address
MAHARASHTRA
Mumbai
Almac House, Senapati Bapat Marg
Contacts
+912239829999
www.alkemlabs.com